We are live on ! Find out more
ANIK icon

Anika Therapeutics
ANIK

162 hedge funds and large institutions have $537M invested in Anika Therapeutics in 2016 Q1 according to their latest regulatory filings, with 24 funds opening new positions, 60 increasing their positions, 55 reducing their positions, and 14 closing their positions.

New
Increased
Maintained
Reduced
Closed

71% more first-time investments, than exits

New positions opened: 24 | Existing positions closed: 14

57% more call options, than puts

Call options by funds: $2.38M | Put options by funds: $1.51M

13% more capital invested

Capital invested by funds: $474M → $537M (+$63.1M)

7% more funds holding

Funds holding: 152 → 162 (+10)

9% more repeat investments, than reductions

Existing positions increased: 60 | Existing positions reduced: 55

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

Holders
162
Holders Change
+10
Holders Change %
+6.58%
% of All Funds
4.32%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.05%
New
24
Increased
60
Reduced
55
Closed
14
Calls
$2.38M
Puts
$1.51M
Net Calls
+$864K
Net Calls Change
-$382K

Top Buyers

1
Renaissance Technologies
Renaissance Technologies
New York
+$7.6M
2
FAM
Fred Alger Management
New York
+$5.63M
3
CM
Capital Management
Virginia
+$4.76M
4
HP
HealthInvest Partners
Sweden
+$4.53M
5
NAP
New Amsterdam Partners
New York
+$4.39M

Top Sellers

1
PCM
Portolan Capital Management
Massachusetts
-$14.5M
2
CSC
Cove Street Capital
California
-$12.9M
3
LCP
Lombardia Capital Partners
California
-$8.83M
4
TSW
Thompson Siegel & Walmsley
Virginia
-$8.67M
5
Millennium Management
Millennium Management
New York
-$4.22M
Name Holding Trade Value Shares
Change 		Change in
Stake
QCG
176
Quadrant Capital Group
Ohio
– +$811 +20 New
4 5 6 7
8

ANIK Hedge Fund Activity: Q1 2016 in Review

162 of the 3,753 institutional investors tracked by Wall St. Rank reported a position in Anika Therapeutics (ANIK) for Q1 2016, worth a combined $537M — up 13% from $474M a quarter earlier.

Buyers outnumbered sellers: 24 funds opened new ANIK positions and 14 closed out — a net gain of 10 holders — while 60 added to existing stakes and 55 trimmed.

The largest buyer was Renaissance Technologies, adding an estimated $7.6M. The largest seller was Portolan Capital Management, cutting an estimated $14.5M.

  • 162 institutional investors held Anika Therapeutics (ANIK) as of Q1 2016, up from 152 in Q4 2015.
  • Funds reported $537M of Anika Therapeutics stock for Q1 2016, up 13% quarter-over-quarter.
  • 24 funds opened new Anika Therapeutics positions in Q1 2016 and 14 closed out, a net change of +10 holders.
  • The largest Anika Therapeutics buyer in Q1 2016 was Renaissance Technologies, an estimated $7.6M added.
  • The largest Anika Therapeutics seller in Q1 2016 was Portolan Capital Management, an estimated $14.5M sold.

Based on aggregated 13F filings for Q1 2016.